RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in ...

Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) soared 27% on Monday after the company released encouraging top-line ...

Praxis Precision Medicines, Inc. (($PRAX)) has held its Q2 earnings call. Read on for the main highlights of the call. Praxis Precision Medicines, ...

US$6.60 loss per share (further deteriorated from US$4.58 loss in 1H 2024). AI is about to change healthcare. These 20 stocks ...

Praxis reported a net loss of $69.3 million for the three months ended March 31, 2025, including $8.8 million of stock-based compensation expense, compared to $39.6 million for the three months ...

--Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by ...

Praxis Precision Medicines, Inc. announced significant advancements in its clinical portfolio, highlighting three late-stage assets poised for potential blockbuster status and the expectation of ...

Praxis Precision Medicines is developing a first-in-class drug in MDD. See why we recommend PRAX stock as a core investment in anticipation of clinical trials.

BOSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Praxis Precision Medicines, a clinical-stage, genetic neuroscience company, launched today with more than $100 million in financing since its inception from ...

Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study ...